Western Regional Blog – BC, YK, AB, NWT and Nunavut
“Over the next 5 years, we will see a dramatic surge forward in our understanding of the molecular basis of the less-common subtypes of ovarian carcinoma (LGSC, EC, MC and CCC), which together account for 30% of cases. There will be increasing efforts to offer subtype-specific treatment for ovarian carcinoma, based on our improved understanding of the different biologies of these subtypes.”
Chris M.J. Conklin, MD; C. Blake Gilks, MD, FRCPC
The five main subtypes of ovarian surface epithelial carcinoma (high-grade serous, low-grade serous, endometrioid, clear cell and mucinous) are different diseases, with differences in genetic and environmental risk factors, precursor lesions, molecular events during oncogenesis, patterns of spread and response to treatment. With recent advances in surgical pathology, it is possible to reproducibly diagnose these subtypes in routine surgical pathology practice. This review examines these subtypes of ovarian carcinoma, focusing on differential diagnosis, molecular features and current treatment strategies. The increasing understanding of the molecular abnormalities associated with each subtype is leading to exploration and introduction of more subtype-specific treatment of ovarian carcinoma.
Key Issues –
More than 98% of ovarian surface epithelial carcinomas can be assigned to one of five major subtypes: high-grade serous carcinoma, clear cell carcinoma, endometrioid carcinoma, mucinous carcinoma and low-grade serous carcinoma. The five main subtypes have distinct molecular abnormalities and treatment responses, and are best regarded as distinct diseases.